Niagen Bioscience Inc

NASDAQ:NAGE

Biotechnology

Healthcare
$1.94 +3.31%

+$0.11 today

Market cap
$153.64M
Beta
2.06
P/E (TTM)
14.9
EPS (TTM)
$0.23
52W Low $3.35High $14.69

Volume 0.52M

Average 0.86M

Returns on capital

Niagen Bioscience Inc management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

22.7%

avg -56.7%

ROIC

15.6%

avg -45.9%

ROA

16.3%

avg -28.7%

Analysis

ROE is currently the strongest return metric at 22.7% versus its period average of -56.7%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Robert N. Fried

Chief Executive Officer & DirectorUSD 1.21M661.06M1.33%

Ozan Pamir

Chief Financial Officer & Principal Accounting OfficerUSD 648.24K3411.63K0.01%

Carlos Lopez

Senior Vice President & General CounselUSD 480.03K45——

James Lee

ControllerUSD 286.49K50——

Frank Louis Jaksch Jr.

Co-Founder & ChairmanUSD 70K58——

Michiko Kelley

Chief Marketing Officer————

Wesley Yu

Vice President of Finance————

Andrew Shao

Senior Vice President of Global Regulatory & Scientific Affairs————

Kendall Knysch

Head of Media Relations & Partnerships————

Chu Yan

Managing Director of Asia Pacific————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 30, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
+15.4% (5yr)1 analysts
RevenueN/AN/A+21.6%
+12.5% (5yr)1 analysts
Net IncomeN/AN/AN/A
+15.0% (5yr)1 analysts
EBITN/AN/AN/A
+25.4% (5yr)1 analysts

Analysis

Recent growth has been strongest in Revenue at +21.6% over three years. Forward estimates point to EBIT at +25.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Niagen Bioscience Inc compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NAGE's management, answered from reported figures.

Who manages NAGE?

Niagen Bioscience Inc (NAGE) lists 10 active executives. The top listed executive is Ozan Pamir, Chief Financial Officer & Principal Accounting Officer.

Are NAGE insiders buying or selling?

Recent insider activity shows net buying of $5.81M.